M&A Deal Summary

ArchiMed Acquires Aliri

On July 16, 2021, private equity firm ArchiMed acquired life science company Aliri

Acquisition Highlights
  • This is ArchiMed’s 6th transaction in the Life Science sector.
  • This is ArchiMed’s 5th transaction in the United States.
  • This is ArchiMed’s 1st transaction in Colorado.

M&A Deal Summary

Date 2021-07-16
Target Aliri
Sector Life Science
Buyer(s) ArchiMed
Deal Type Buyout (LBO, MBO, MBI)

Target

Aliri

Colorado Springs, Colorado, United States
Aliri is a provider of molecular imaging services and products aiming at enhancing the development of new drugs through innovative proprietary technologies. Aliri was founded in 1991 and is based in Colorado Springs, Colorado.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

ArchiMed

Investor Investor Investor Investor Investor


Category Private Equity Firm
Founded 2014
PE ASSETS 8.0B EUR
Size Mega
Type Sector Focused
DESCRIPTION

ArchiMed is a specialist French private equity firm focused on buyouts of and growth capital investments in European healthcare-oriented companies. The Firm looks to invest €10 million to €1 billion per transaction and specifically targets companies in the public health, care and wellness, biotech, and medical technology segments of the healthcare industry. ArchiMed was formed in 2014 and is headquartered in Lyon.


DEAL STATS #
Overall 23 of 38
Sector: Life Science M&A 6 of 14
Type: Buyout (LBO, MBO, MBI) M&A Deals 15 of 21
State: Colorado M&A 1 of 2
Country: United States M&A 5 of 11
Year: 2021 M&A 4 of 9
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-06-24 Stragen Pharma

Geneva, Switzerland

Stragen Pharma is a developer of hard-to-make, complex generic drugs for the treatment of patients with life-threatening conditions that require comprehensive care and monitoring, usually in intensive care units. Stragen Pharma was founded in 1990 and is based in Geneva, Switzerland.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-10-05 Xpress Biologics

Milmort, Belgium

Xpress Biologics is a developer of expression systems and manufacturing processes for the production of plasmid DNA and protein therapeutics. Xpress Biologics was founded in 2014 and is based in Milmort, Belgium.

Buy -